Transcenta Holding Limited (HKG:6628)
Hong Kong
· Delayed Price · Currency is HKD 2.320
+0.230 (11.00%)
At close: Mar 10, 2026
Transcenta Holding Revenue
Transcenta Holding had revenue of 2.71M CNY in the half year ending June 30, 2025, a decrease of -92.49%. This brings the company's revenue in the last twelve months to 9.41M, down -57.87% year-over-year. In the year 2024, Transcenta Holding had annual revenue of 11.26M, down -79.09%.
Revenue (ttm)
9.41M CNY
Revenue Growth
-57.87%
P/S Ratio
101.25
Revenue / Employee
55.02K CNY
Employees
171
Market Cap
1.04B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Brii Biosciences | 31.53M |
| Sunho Biologics | 18.63K |
| 3D Medicines | 491.34M |
| Wuhan YZY Biopharma | 163.65M |
| JW (Cayman) Therapeutics Co. | 194.77M |
| Beijing Biostar Pharmaceuticals | 58.66M |
| CANbridge Pharmaceuticals | 68.55M |
| Kintor Pharmaceutical | 12.04M |
Transcenta Holding News
- 2 months ago - Transcenta Collaborates With EirGenix To License HiCB Platform - Nasdaq